Ginsenoside Rh2 improves the cisplatin anti-tumor effect in lung adenocarcinoma A549 cells via superoxide and PD-L1.
Ginsenoside Rh2 (Rh2) is a major biological component of ginseng that exerts anti-tumor activities in multiply cancers including Non-Small Cell Lung Cancers (NSCLCs). Rh2 also enhance the anti-tumor effects of various chemotherapy drugs including cisplatin at relatively low concentrations. Here, the mechanistic role of Rh2 in chemotherapy-treated NSCLCs will be investigated. In this study, FACS, western blot and siRNA addition were used to analyze the role of Rh2 in cisplatin-treated lung adenocarcinoma A549 and H1299 cells. Subsequent observations indicated that Rh2 enhanced cisplatin-induced NSCLCs A549 and H1299 cells apoptosis. Cisplatin-induced productive autophagy was repressed by Rh2 in A549 cells. Rh2 also enhanced cisplatin cytotoxicity by elevating superoxide dismutase activity and repressing cisplatin-induced superoxide generation. Conversely, Rh2 was found to repress cisplatin-induced phosphorylation of epidermal growth factor receptor, phosphoinositide 3-kinase, protein kinase B, and autophagy. Cisplatin-induced Programmed Death-Ligand 1 (PD-L1) expression was repressed by Rh2 via the superoxide. These findings suggest that Rh2 enhanced the function of cisplatin by repressing superoxide generation, PD-L1 expression, and autophagy in lung adenocarcinoma cells.